Literature DB >> 26666762

Wenxia Changfu Formula () induces apoptosis of lung adenocarcinoma in a transplanted tumor model of drug-resistance nude mice.

Xu-Ming Ji1, Zhi-Chun Wu2, Guo-Wei Liu1, Hua-Yun Yu1, Heng Liu3, Zheng-Tao Wang4, Xiao-Hui Wei4, Bing Ouyang1.   

Abstract

OBJECTIVE: To explore the apoptosis mechanism of Wenxia Changfu Formula (, WCF) in reversing drug resistance of lung cancer in vivo.
METHODS: Thirty model mice were randomly assigned to three groups: control group, cisplatin (CDDP) group, and WCF group. A transplanted tumor model of lung adenocarcinoma was established in all groups. Mice in the WCF group received intragastric administration of WCF (0.2 mL/10 g body weight) everyday in addition to CDDP intraperitoneally (5 mg/kg body weight) twice a week. The mice in the CDDP group received CDDP intraperitoneally (5 mg/kg body weight) twice a week, while the control group received normal saline intraperitoneally (0.2 mL/10 g body weight) everyday. The weight of the nude mice and respective tumors, tumor volume and tumor-inhibiting rate were measured. Electron microscopy was used to observe the existence of apoptosis body. Apoptosis index (AI) was detected by TdT-mediated dUTP nick end labeling staining. The expression of Fas and FasL mRNA was investigated by reverse transcription polymerase chain reaction, while immunohistochemistry was applied to detect the protein expression of Fas and FasL, caspase-3 and caspase-activated DNase (CAD), respectively.
RESULTS: Compared with CDDP group and control group, WCF could significantly reduce the tumor volume from the 19th day and alleviate the tumor weight (P <0.05), and the apoptosis body was found in tumor cells in the WCF group. WCF could also enhance the level of AI, up-regulate the expression of caspase apoptosis pathway related protein caspase-3 and CAD, as well as the expression of Fas, FasL mRNA and protein (P <0.05).
CONCLUSION: WCF could improve the sensitivity of tumor cells to CDDP and reverse the drug resistance by inducing the apoptosis.

Entities:  

Keywords:  Wenxia Changfu Formula; animal model; apoptosis; drug resistance; in vivo

Mesh:

Substances:

Year:  2015        PMID: 26666762     DOI: 10.1007/s11655-015-2087-4

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  16 in total

Review 1.  The 'complexities' of life and death: death receptor signalling platforms.

Authors:  Laura S Dickens; Ian R Powley; Michelle A Hughes; Marion MacFarlane
Journal:  Exp Cell Res       Date:  2012-04-17       Impact factor: 3.905

2.  Repression of E-cadherin by the polycomb group protein EZH2 in cancer.

Authors:  Q Cao; J Yu; S M Dhanasekaran; J H Kim; R-S Mani; S A Tomlins; R Mehra; B Laxman; X Cao; J Yu; C G Kleer; S Varambally; A M Chinnaiyan
Journal:  Oncogene       Date:  2008-09-22       Impact factor: 9.867

3.  Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo.

Authors:  Sha Hu; Lili Yu; Zhimin Li; Yi Shen; Jing Wang; Jing Cai; Lan Xiao; Zehua Wang
Journal:  Cancer Biol Ther       Date:  2010-10-15       Impact factor: 4.742

Review 4.  Antibody-based fusion proteins to target death receptors in cancer.

Authors:  Marco de Bruyn; Edwin Bremer; Wijnand Helfrich
Journal:  Cancer Lett       Date:  2011-01-06       Impact factor: 8.679

5.  Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.

Authors:  Phillip H Abbosh; John S Montgomery; Jason A Starkey; Milos Novotny; Eleanor G Zuhowski; Merrill J Egorin; Annie P Moseman; Adam Golas; Kate M Brannon; Curtis Balch; Tim H M Huang; Kenneth P Nephew
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

6.  Newcastle disease virus induces apoptosis in cisplatin-resistant human lung adenocarcinoma A549 cells in vitro and in vivo.

Authors:  Songshu Meng; Zhizhi Zhou; Fei Chen; Xiangang Kong; Huairan Liu; Ke Jiang; Wenbo Liu; Maozhi Hu; Xiaorong Zhang; Chan Ding; Yantao Wu
Journal:  Cancer Lett       Date:  2011-11-15       Impact factor: 8.679

7.  Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2.

Authors:  Andrei V Ougolkov; Vladimir N Bilim; Daniel D Billadeau
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

8.  Tobacco smoke induces polycomb-mediated repression of Dickkopf-1 in lung cancer cells.

Authors:  Mustafa Hussain; Mahadev Rao; Ashley E Humphries; Julie A Hong; Fang Liu; Maocheng Yang; Diana Caragacianu; David S Schrump
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

9.  Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells.

Authors:  Satoshi Fujii; Atsushi Ochiai
Journal:  Cancer Sci       Date:  2008-04       Impact factor: 6.716

10.  Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma.

Authors:  Heidi Schwarzenbach
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

View more
  3 in total

1.  Chinese Herbal Medicine Wenxia Changfu Formula Reverses Cell Adhesion-Mediated Drug Resistance via the Integrin β1-PI3K-AKT Pathway in Lung Cancer.

Authors:  YaNan Zhang; ZhiChun Wu; HuaYun Yu; HuaXin Wang; Guowei Liu; ShiJun Wang; XuMing Ji
Journal:  J Cancer       Date:  2019-01-01       Impact factor: 4.207

2.  Cordyceps militaris induces apoptosis in ovarian cancer cells through TNF-α/TNFR1-mediated inhibition of NF-κB phosphorylation.

Authors:  Eunbi Jo; Hyun-Jin Jang; Kyeong Eun Yang; Min Su Jang; Yang Hoon Huh; Hwa-Seung Yoo; Jun Soo Park; Ik-Soon Jang; Soo Jung Park
Journal:  BMC Complement Med Ther       Date:  2020-01-13

3.  N-Butanol Fraction of Wenxia Formula Extract Inhibits the Growth and Invasion of Non-Small Cell Lung Cancer by Down-Regulating Sp1-Mediated MMP2 Expression.

Authors:  QianYu Bi; MengRan Wang; Fang Zhao; Meng Wang; XiangJun Yin; JiaZhao Ruan; DeLong Wang; XuMing Ji
Journal:  Front Pharmacol       Date:  2020-11-30       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.